Raymond James Issues Negative Forecast for TSE:MDP Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Analysts at Raymond James reduced their Q3 2025 earnings per share estimates for Medexus Pharmaceuticals in a report released on Tuesday, January 7th. Raymond James analyst M. Freeman now anticipates that the company will post earnings of ($0.03) per share for the quarter, down from their prior estimate of $0.01. Raymond James has a “Strong-Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at $0.03 EPS and Q1 2026 earnings at $0.23 EPS.

Other research analysts also recently issued research reports about the company. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Leede Financial set a C$8.25 target price on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research report on Monday, September 30th. Two research analysts have rated the stock with a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, Medexus Pharmaceuticals currently has a consensus rating of “Strong Buy” and a consensus price target of C$5.25.

Medexus Pharmaceuticals Stock Up 13.1 %

Shares of Medexus Pharmaceuticals stock opened at C$4.07 on Friday. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$4.07. The business’s fifty day simple moving average is C$2.74 and its 200-day simple moving average is C$2.52. The firm has a market cap of C$99.84 million, a PE ratio of 81.40 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.